Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma-Reference-Cited by-同舟云学术

Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma

Published:2014-08-21 Issue:8 Volume:124 Page:1300-1303
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Paiva Bruno¹,Chandia Mauricio²,Vidriales Maria-Belen²,Colado Enrique³,Caballero-Velázquez Teresa⁴,Escalante Fernando⁵,Garcia de Coca Alfonso⁶,Montes Maria-Carmen⁷,Garcia-Sanz Ramon²,Ocio Enrique M.²,Mateos Maria-Victoria²,San Miguel Jesus F.¹

Affiliation:

1. Centro de Investigación Medica Aplicada, Clinica Universidad de Navarra, Pamplona, Spain;

2. Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto Mixto Consejo Superior de Investigaciones Científicas–Universidad de Salamanca Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Salamanca, Spain;

3. Hospital Universitario Central de Asturias, Oviedo, Spain;

4. Hospital Universitario Virgen del Rocio/Consejo Superior de Investigaciones Científicas/Universidad de Sevilla, Instituto de Biomedicina de Sevilla, Sevilla, Spain;

5. Complejo Hospitalario de Leon, Leon, Spain;

6. Hospital Clinico Universitario de Valladolid, Valladolid, Spain; and

7. Hospital Virgen de la Concha, Zamora, Spain

Abstract

Key Points MFC is a valuable biomarker to discriminate “true” SBP patients from those with “occult” BM clonal PCs and high-risk of progression to MM.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/8/1300/1381900/1300.pdf

Reference12 articles.